MARKET

ARQL

ARQL

ArQule
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.00
+0.03
+0.15%
Delisted 09:30 01/24 EST
OPEN
20.00
PREV CLOSE
19.97
HIGH
20.00
LOW
19.98
VOLUME
6.17M
TURNOVER
--
52 WEEK HIGH
20.45
52 WEEK LOW
3.150
MARKET CAP
2.41B
P/E (TTM)
-58.1564
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ARQL and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ARQL News

  • ArQule, Inc. (ARQL) vs. Top 20 Hedge Fund Stocks in 2019
  • Insider Monkey.01/13 14:34
  • These Were the 10 Best Stocks of 2019
  • MotleyFool.com.01/06 17:13
  • Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the Firm
  • PR Newswire.01/06 16:07
  • Why Biotech Stock ArQule Soared 108% in December
  • MotleyFool.com.01/04 12:00

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About ARQL

ArQule, Inc. is a biopharmaceutical company that is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of approximately four drug candidates, all of which are in targeted patient populations. The Company's product candidates include ARQ 531, Miransertib (ARQ 092), ARQ 751, Miransertib (ARQ 092) and ARQ 751. ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). ARQ 092 is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase. ARQ 751 is a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K). ARQ 087 is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast.
More

Webull offers ArQule, Inc. (ARQL) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.